Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Portfolio Pulse from Lisa Levin
Avid Bioservices shares fell 14.1% after issuing FY24 revenue guidance below estimates. Other stocks experienced significant gains and losses during Thursday's mid-day session, with Aeglea BioTherapeutics climbing 422% after acquiring Spyre Therapeutics and securing a $210 million private investment.
June 22, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aeglea BioTherapeutics shares climbed 422% after the company announced the acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private investment positions.
Aeglea BioTherapeutics' acquisition of Spyre Therapeutics and the concurrent oversubscribed $210 million private investment positions the company for growth and expansion, leading to a significant increase in its share price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Avid Bioservices shares fell 14.1% after the company issued FY24 revenue guidance below estimates.
Avid Bioservices issued FY24 revenue guidance below market estimates, which has led to a decline in its share price. Investors may be concerned about the company's future growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100